Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria-Reference-Cited by-同舟云学术

Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria

Published:2014-10-30 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Martí-Carvajal Arturo J¹,Anand Vidhu²,Cardona Andrés Felipe³,Solà Ivan⁴

Affiliation:

1. Iberoamerican Cochrane Network; Valencia Venezuela

2. University of Minnesota; Department of Medicine; 420 Delaware Street SE Mayo Mail Code 195 Minneapolis MN USA 55455

3. Institute of Oncology, Fundación Santa Fe de Bogotá; Clinical and Translational Oncology Group; Calle 119 No. 7 - 75 Bogotá Cundinamarca Colombia 0571

4. CIBER Epidemiología y Salud Pública (CIBERESP); Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau); Sant Antoni Maria Claret 171 - Edifici Casa de Convalescència Barcelona Catalunya Spain 08041

Publisher

Wiley

Subject

Pharmacology (medical)

Reference201 articles.

1. Brodsky RA Muus P Dührsen U Hill A Bessler M Coutre S Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results Blood (ASH Annual Meeting Abstracts) 2006 3770

2. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria;Hill;British Journal of Haematology,2010

3. Eculizumab reduces pulmonary hypertension through inhibition of hemolysis-associated nitric oxide consumption in patients with paroxysmal nocturnal hemoglobinuria;Hill;Blood,2009

4. TRIUMPH, a randomized placebo-controlled phase III trial, demonstrates that the terminal complement inhibitor eculizumab improves anaemia in PNH;Hill;British Journal of Haematology,2007

5. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria;Hillmen;American Journal of Hematology,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease;Medicina;2023-11-16

2. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria;Haematologica;2022-03-10

3. Experienced fatigue in people with rare disorders: a scoping review on characteristics of existing research;Orphanet Journal of Rare Diseases;2022-01-10

4. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis;Journal of Pediatric Hematology/Oncology;2021-04-26

5. The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health;Revista de Saúde Pública;2020-02-13